Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.

MLA

Drakopoulos, Panagiotis, et al. “Corifollitropin Alfa Followed by Highly Purified HMG versus Recombinant FSH in Young Poor Ovarian Responders: A Multicentre Randomized Controlled Clinical Trial.” Human Reproduction (Oxford, England), vol. 32, no. 11, Nov. 2017, pp. 2225–33. EBSCOhost, https://doi.org/10.1093/humrep/dex296.

APA

Drakopoulos, P., Vuong, T. N. L., Ho, N. A. V., Vaiarelli, A., Ho, M. T., Blockeel, C., Camus, M., Lam, A. T., van de Vijver, A., Humaidan, P., Tournaye, H., & Polyzos, N. P. (2017). Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Human Reproduction (Oxford, England), 32(11), 2225–2233. https://doi.org/10.1093/humrep/dex296

Chicago

Drakopoulos, Panagiotis, Thi Ngoc Lan Vuong, Ngoc Anh Vu Ho, Alberto Vaiarelli, Manh Tuong Ho, Christophe Blockeel, Michel Camus, et al. 2017. “Corifollitropin Alfa Followed by Highly Purified HMG versus Recombinant FSH in Young Poor Ovarian Responders: A Multicentre Randomized Controlled Clinical Trial.” Human Reproduction (Oxford, England) 32 (11): 2225–33. doi:10.1093/humrep/dex296.